
Treatment with the Revi System led to durable QOL benefits at 24 months, even among those patients who did not achieve the primary end point.

Treatment with the Revi System led to durable QOL benefits at 24 months, even among those patients who did not achieve the primary end point.

Nearly 60% of patients taking vibegron remained on treatment at 1 year.